These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29389577)

  • 21. Creatinine normalization of workplace urine drug tests: does it make a difference?
    Price JW
    J Addict Med; 2013; 7(2):129-32. PubMed ID: 23370934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can synthetic urine replace authentic urine to "beat" workplace drug testing?
    Kim VJ; Okano CK; Osborne CR; Frank DM; Meana CT; Castaneto MS
    Drug Test Anal; 2019 Feb; 11(2):331-335. PubMed ID: 30194711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine toxicology screening by liquid chromatography time-of-flight mass spectrometry in a quaternary hospital setting.
    Pope JD; Black MJ; Drummer OH; Schneider HG
    Clin Biochem; 2021 Sep; 95():66-72. PubMed ID: 33989561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exhaled breath for drugs of abuse testing - evaluation in criminal justice settings.
    Beck O
    Sci Justice; 2014 Jan; 54(1):57-60. PubMed ID: 24438778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substance abuse monitoring by the Correctional Service of Canada.
    Fraser AD; Zamecnik J
    Ther Drug Monit; 2002 Feb; 24(1):187-91. PubMed ID: 11805743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations.
    Cone EJ; Presley L; Lehrer M; Seiter W; Smith M; Kardos KW; Fritch D; Salamone S; Niedbala RS
    J Anal Toxicol; 2002; 26(8):541-6. PubMed ID: 12501910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fast screening tests for the simultaneous detection of 11 drugs of abuse in urine specimens. A forensic epidemiology study of 28,298 cases in Tunisia.
    Moslah B; Araoud M; Nouioui MA; Najjar S; Amira D; Ben Salah N; Hedhili A
    Forensic Sci Int; 2018 Feb; 283():35-40. PubMed ID: 29248810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance evaluation of four on-site drug-testing devices for detection of drugs of abuse in urine.
    Peace MR; Tarnai LD; Poklis A
    J Anal Toxicol; 2000 Oct; 24(7):589-94. PubMed ID: 11043664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous determination of 11 β-agonists in human urine using high-performance liquid chromatography/tandem mass spectrometry with isotope dilution.
    Wang X; Guo T; Wang S; Yuan J; Zhao R
    J Anal Toxicol; 2015 Apr; 39(3):213-8. PubMed ID: 25542892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drugs of abuse testing safer and safer and more complete].
    Beck O; Villén T
    Lakartidningen; 2011 Oct 9-15; 108(45):2300-3. PubMed ID: 22242246
    [No Abstract]   [Full Text] [Related]  

  • 32. Choosing the right laboratory: a review of clinical and forensic toxicology services for urine drug testing in pain management.
    Reisfield GM; Goldberger BA; Bertholf RL
    J Opioid Manag; 2015; 11(1):37-44. PubMed ID: 25750163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 6-year experience with urine drug testing by family service agencies in Nova Scotia, Canada.
    Fraser AD
    Forensic Sci Int; 2001 Oct; 121(3):151-6. PubMed ID: 11566417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid.
    Cone EJ; Clarke J; Tsanaclis L
    J Anal Toxicol; 2007 Oct; 31(8):424-33. PubMed ID: 17988455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A snapshot of workplace drug testing in Italy.
    Santoro PE; De Nardis I; Fronterrè P; Felli M; Martello S; Bergamaschi A; Chiarotti M
    Drug Test Anal; 2012 Feb; 4(2):66-70. PubMed ID: 22362571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating Novel Markers for Specimen Validity Testing.
    Kyle PB; Kaur J
    Arch Pathol Lab Med; 2020 Feb; 144(2):168-171. PubMed ID: 31755779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of saliva and fingerprints as alternative specimens to urine and blood in forensic drug testing.
    Kuwayama K; Miyaguchi H; Yamamuro T; Tsujikawa K; Kanamori T; Iwata YT; Inoue H
    Drug Test Anal; 2016 Jul; 8(7):644-51. PubMed ID: 26074137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Workplace drug testing on urine samples: evidence for improving efficacy of a first-level screening programme.
    Crespi V; Maio RC; Veronesi G; Gianfagna F; Taborelli S; Ferrario MM
    Med Lav; 2015 Sep; 106(5):374-85. PubMed ID: 26384263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Workplace drug testing in Italy: findings about second-stage testing.
    Vignali C; Stramesi C; Morini L; San Bartolomeo P; Groppi A
    Drug Test Anal; 2015 Mar; 7(3):173-7. PubMed ID: 24652693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing.
    Castaneto MS; Barnes AJ; Concheiro M; Klette KL; Martin TA; Huestis MA
    Anal Bioanal Chem; 2015 Jun; 407(16):4639-48. PubMed ID: 25903022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.